Plasma biomarkers have recently emerged for the diagnosis, assessment, and disease monitoring of Alzheimer's disease (AD), but have yet to be fully validated in preclinical AD. In addition to AD pathologic plasma biomarkers (amyloid-β (Aβ) and phosphorylated tau (p-tau) species), a proteomic panel can discriminate between symptomatic AD and cognitively unimpaired older adults in a dementia clinic population.
Objective
Examine the added value of a plasma proteomic panel, validated in symptomatic AD, over standard AD pathologic plasma biomarkers and demographic and genetic (apolipoprotein (APOE) ɛ4 status) risk factors in detecting preclinical AD.
Methods
125 cognitively unimpaired older adults (mean age = 66 years) who completed Aβ PET and plasma draw were analyzed using multiple regression with Aβ PET status (positive versus negative) as the outcome to determine the best fit for predicting preclinical AD. Model 1 included age, education, and gender. Model 2 and 3 added predictors APOE ɛ4 status (carrier versus non-carrier) and AD pathologic blood biomarkers (Aβ42/40 ratio, p-tau181), respectively. Random forest modeling established the 5 proteomic markers from the proteomic panel that best predicted Aβ PET status, and these markers were added in Model 4.
Results
The best model for predicting Aβ PET status included age, years of education, APOE ɛ4 status, Aβ42/40 ratio, and p-tau181. Adding the top 5 proteomic markers did not significantly improve the model.
Conclusions
Proteomic markers in plasma did not add predictive value to standard AD pathologic plasma biomarkers in predicting preclinical AD in this sample.
2023 Alzheimer’s disease facts and figures. Alzheimers Dement2023; 19: 1598–1695.
2.
HebertLEWeuveJScherrPA, et al.Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology2013; 80: 1778–1783.
3.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 280–292.
4.
UddinMSKabirMTAl MamunA, et al.APOE And Alzheimer’s disease: evidence mounts that targeting APOE4 may combat Alzheimer’s pathogenesis. Mol Neurobiol2019; 56: 2450–2465.
5.
PrinsSde KamMLTeunissenCE, et al.Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease. Alzheimers Res Ther2022; 14: 106.
6.
LangloisCMBradburyAWoodEM, et al.Alzheimer’s prevention initiative generation program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y)2019; 5: 705–716.
7.
DoeckeJDPérez-GrijalbaVFandosN, et al.Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology2020; 94: 15.
8.
AshtonNJPascoalTAKarikariTK, et al.Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol2021; 141: 709–724.
9.
Milà-AlomàMSuárez-CalvetMMolinuevoJL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord2019; 12: 1–23.
10.
KarikariTKBenedetALAshtonNJ, et al.Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s disease neuroimaging initiative. Mol Psychiatry2021; 26: 429–442.
11.
KarikariTKPascoalTAAshtonNJ, et al.Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol2020; 19: 422–433.
12.
PalmqvistSJanelidzeSQuirozYT, et al.Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA2020; 324: 772–781.
13.
FandosNPérez-GrijalbaVPesiniP, et al.Plasma Aβ42/40 ratios as biomarkers for Aβ cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst)2017; 8: 179–187.
14.
JonaitisEMJanelidzeSCodyKA, et al.Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease. Brain Commun2023; 5: fcad057.
15.
JackCRBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement2018; 14: 535–562.
16.
HenekaMTCarsonMJKhouryJ, et al.Neuroinflammation in Alzheimer’s disease. Lancet Neurol2015; 14: 388–405.
17.
NovoaCSalazarPCisternasP, et al.Inflammation context in Alzheimer’s disease, a relationship intricate to define. Biol Res2022; 55: 39.
18.
SantosCYSnyderPJWuW-C, et al.Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement (Amst)2017; 7: 69–87.
19.
BenedetALAshtonNJPascoalTA, et al.Plasma neurofilament light associates with Alzheimer’s disease metabolic decline in amyloid-positive individuals. Alzheimers Dement (Amst)2019; 11: 679–689.
20.
O’BryantSE. A serum protein–based algorithm for the detection of Alzheimer disease. Arch Neurol2010; 67: 1077.
21.
O’BryantSEXiaoGBarberR, et al.A blood-based screening tool for Alzheimer’s disease that spans serum and plasma: findings from TARC and ADNI. PLoS One2011; 6: e28092.
22.
O’BryantSEXiaoGZhangF, et al.Validation of a serum screen for Alzheimer’s disease across assay platforms, species, and tissues. J Alzheimers Dis2014; 42: 1325–1335.
23.
O’BryantSEEdwardsMJohnsonL, et al.A blood screening test for Alzheimer’s disease. Alzheimers Dement (Amst)2016; 3: 83–90.
24.
PletnikovaOKageyamaYRudowG, et al.The spectrum of preclinical Alzheimer’s disease pathology and its modulation by ApoE genotype. Neurobiol Aging2018; 71: 72–80.
25.
MurphyKRLandauSMChoudhuryKR, et al.Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. Neuroimage2013; 78: 474–480.
26.
MorrisJCRoeCMXiongC, et al.APOE Predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol2010; 67: 122–131.
27.
LimYYVillemagneVLPietrzakRH, et al.APOE Ε4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurobiol Aging2015; 36: 1239–1244.
28.
MorminoECBetenskyRAHeddenT, et al.Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology2014; 82: 176–1777.
29.
ClarkCM. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA2011; 305: 275.
30.
CamusVPayouxPBarréL, et al.Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging2012; 39: 621–631.
31.
JoshiADPontecorvoMJLuM, et al.A semiautomated method for quantification of F 18 Florbetapir PET images. J Nucl Med2015; 56: 1736–1741.
32.
LandauSMBreaultCJoshiAD, et al.Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med2013; 54: 70–77.
33.
O’BryantSEGuptaVHenriksenK, et al.Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement2015; 11: 549–560.
34.
LeeAMenardWToniniG, et al.Reliability of a rapid APOE assay for Alzheimer’s risk assessment and clinical trial screening. J Prev Alzheimers Dis2018; 5: 182.
35.
Van BuurenSGroothuis-OudshoornK. Mice: multivariate imputation by chained equations in R. J Stat Softw2011; 45: 1–67.
Díaz-UriarteRAlvarez de AndrésS. Gene selection and classification of microarray data using random forest. BMC Bioinformatics2006; 7: 3.
38.
WuBAbbottTFishmanD, et al.Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics2003; 19: 1636–1643.
39.
FinehoutEJFranckZChoeLH, et al.Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol2007; 61: 120–129.
40.
LehmannCKoenigTJelicV, et al.Application and comparison of classification algorithms for recognition of Alzheimer’s disease in electrical brain activity (EEG). J Neurosci Methods2007; 161: 342–350.
41.
TripolitiEEFotiadisDIArgyropoulouM. An automated supervised method for the diagnosis of Alzheimer’s disease based on fMRI data using weighted voting schemes. In: 2008 IEEE International Workshop on Imaging Systems and Techniques, pp.340–345: IEEE.
42.
O’BryantSEXiaoGBarberR, et al.Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord2014; 37: 45–57.
43.
O’BryantSEXiaoGBarberR, et al.A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol2010; 67: 1077–1081.
44.
BreimanL. Random forests. Mach Learn2001; 45: 5–32.
45.
ZotovaENicollJAKalariaR, et al.Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers Res Ther2010; 2: 1.
46.
HansenDVHansonJEShengM. Microglia in Alzheimer’s disease. J Cell Biol2018; 217: 459–472.
47.
KinneyJWBemillerSMMurtishawAS, et al.Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y)2018; 4: 575–590.
48.
LengFEdisonP. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?Nat Rev Neurol2021; 17: 157–172.
TaoQAlvin AngTFAkhter-KhanSC, et al.Impact of C-reactive protein on cognition and Alzheimer disease biomarkers in homozygous APOE ɛ4 carriers. Neurology2021; 97: e1243–e1252.
51.
CaoXChenP. Changes in serum amyloid A (SAA) and 8-OHdG in patients with senile early cognitive impairment. Med Sci Monitor2020; 26: e919586–1.
52.
ChenJDaiAXTangHL, et al.Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer’s disease. Front Immunol2023; 13: 1097409.
53.
PlantoneDPardiniMRighiD, et al.The role of TNF-α in Alzheimer’s disease: a narrative review. Cells2024; 13: 54.
54.
WatermeyerTJRaymontVRitchieK. Neuroinflammation in preclinical Alzheimer’s disease: a review of current evidence. J Alzheimers Dis Parkinsonism2018; 8: 434.
55.
GrossALWalkerKAMoghekarAR, et al.Plasma markers of inflammation linked to clinical progression and decline during preclinical AD. Front Aging Neurosci2019; 11: 229.
56.
MettiALYaffeKBoudreauRM, et al.Trajectories of inflammatory markers and cognitive decline over 10 years. Neurobiol Aging2014; 35: 2785–2790.
57.
WangYGrydelandHRoeJM, et al.Associations of circulating C-reactive proteins, APOE ε4, and brain markers for Alzheimer’s disease in healthy samples across the lifespan. Brain Behav Immun2022; 100: 243–253.
58.
OberlinLEEricksonKIMackeyR, et al.Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-β in cognitively unimpaired older adults. Brain Behav Immun2021; 95: 178–189.
59.
De MeyerSSchaeverbekeJMLuckettES, et al.Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid-PET. Brain Commun2024; 6: fcae162.
60.
FowlerCJStoopsERainey-SmithSR, et al.Plasma p-tau181/Aβ1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ1-42 and future cognitive decline. Alzheimers Dement (Amst)2022; 14: e12375.
61.
YakoubYAshtonNJStrikwerda-BrownC, et al.Longitudinal blood biomarker trajectories in preclinical Alzheimer’s disease. Alzheimers Dement2023; 19: 5620–5631.
62.
SalamiAAdolfssonRAnderssonM, et al.Association of APOE ɛ4 and plasma p-tau181 with preclinical Alzheimer’s disease and longitudinal change in hippocampus function. J Alzheimers Dis2022; 85: 1309–1320.
